Matthew C Dallos
Overview
Explore the profile of Matthew C Dallos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ager C, Obradovic A, McCann P, Chaimowitz M, Wang A, Shaikh N, et al.
medRxiv
. 2024 Sep;
PMID: 39314954
Men with high-risk localized prostate cancer exhibit high rates of post-surgical recurrence. In these patients, androgen deprivation therapy (ADT) is immunomodulatory, however increased infiltration of regulatory T cells (Tregs) may...
2.
Dallos M, Obradovic A, McCann P, Chowdhury N, Pratapa A, Aggen D, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5218-5230.
PMID: 39269310
Purpose: Androgen deprivation therapy (ADT) remains the backbone of prostate cancer treatment. Beyond the suppression of testosterone and tumor cell growth, emerging evidence suggests that ADT also modulates the immune...
3.
Lopez-Bujanda Z, Hadavi S, Ruiz de Porras V, Martinez-Balibrea E, Dallos M
Int Rev Cell Mol Biol
. 2024 Sep;
388:162-205.
PMID: 39260936
Prostate cancer (PCa) stands as a significant global health concern, ranking among the leading causes of cancer deaths in men. While there are several treatment modalities for localized PCa, metastatic...
4.
Hawley J, Obradovic A, Dallos M, Lim E, Runcie K, Ager C, et al.
Cancer Cell
. 2023 Nov;
41(11):1972-1988.e5.
PMID: 37922910
When compared to other malignancies, the tumor microenvironment (TME) of primary and castration-resistant prostate cancer (CRPC) is relatively devoid of immune infiltrates. While androgen deprivation therapy (ADT) induces a complex...
5.
Ager C, Zhang M, Chaimowitz M, Bansal S, Tagore S, Obradovic A, et al.
J Immunother Cancer
. 2023 Sep;
11(9).
PMID: 37657842
Current methods for biomarker discovery and target identification in immuno-oncology rely on static snapshots of tumor immunity. To thoroughly characterize the temporal nature of antitumor immune responses, we developed a...
6.
Ager C, Zhang M, Chaimowitz M, Bansal S, Obradovic A, Rogava M, et al.
bioRxiv
. 2023 Jan;
PMID: 36711647
Current methods for biomarker discovery and target identification in immuno-oncology rely on static snapshots of tumor immunity. To thoroughly characterize the temporal nature of antitumor immune responses, we developed a...
7.
Bukhari S, Henick B, Winchester R, Lerrer S, Adam K, Gartshteyn Y, et al.
Cell Rep Med
. 2022 Dec;
4(1):100868.
PMID: 36513074
PD-1 is an inhibitory receptor in T cells, and antibodies that block its interaction with ligands augment anti-tumor immune responses. The clinical potential of these agents is limited by the...
8.
Runcie K, Dallos M
Curr Oncol Rep
. 2021 Jun;
23(8):88.
PMID: 34125308
Purpose Of Review: Despite significant progress, patients with metastatic prostate cancer continue to have poor prognosis. Immunotherapy has revolutionized cancer care for many tumor types but has a limited role...
9.
Aggen D, Ager C, Obradovic A, Chowdhury N, Ghasemzadeh A, Mao W, et al.
Clin Cancer Res
. 2020 Nov;
27(2):608-621.
PMID: 33148676
Purpose: Intratumoral immunosuppression mediated by myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM) represents a potential mechanism of immune checkpoint inhibitor (ICI) resistance in solid tumors. By promoting TAM and...
10.
Obradovic A, Dallos M, Zahurak M, Partin A, Schaeffer E, Ross A, et al.
Clin Cancer Res
. 2020 Mar;
26(13):3182-3192.
PMID: 32173650
Purpose: Previous studies suggest that androgen deprivation therapy (ADT) promotes antitumor immunity in prostate cancer. Whether a vaccine-based approach can augment this effect remains unknown. Patients And Methods: We conducted...